TOVX Stock Overview
A clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Theriva Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$17.11 |
| 52 Week Low | US$1.22 |
| Beta | 1.34 |
| 11 Month Change | -16.34% |
| 3 Month Change | -63.43% |
| 1 Year Change | -91.13% |
| 33 Year Change | -98.52% |
| 5 Year Change | -98.73% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| TOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | 4.0% | 2.0% |
| 1Y | -91.1% | 18.0% | 32.4% |
Return vs Industry: TOVX underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: TOVX underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| TOVX volatility | |
|---|---|
| TOVX Average Weekly Movement | 29.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TOVX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TOVX's weekly volatility has increased from 19% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Steve Shallcross | therivabio.com |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Theriva Biologics, Inc. Fundamentals Summary
| TOVX fundamental statistics | |
|---|---|
| Market cap | US$3.40m |
| Earnings (TTM) | -US$26.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs TOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.69m |
| Earnings | -US$26.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.7% |
How did TOVX perform over the long term?
See historical performance and comparison